Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 14/20 | 0.65 |
| ▸ | ANPEP | P15144 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22150315 | 1.00 | FPR2 (0.65) | FPR2ANPEPRAB9AMEN1LMNA | |
| SCHEMBL14889863 | 1.00 | FPR2 (0.65) | FPR2ANPEPRAB9AMEN1LMNA | |
| SCHEMBL14890017 | 0.90 | FPR2 (0.81) | FPR2ANPEPMEN1LMNAPOLB | |
| SCHEMBL20983170 | 0.89 | FPR2 (0.74) | FPR2ANPEP | |
| SCHEMBL14890089 | 0.89 | FPR2 (0.74) | FPR2ANPEP | |
| SCHEMBL19201539 | 0.89 | FPR2 (0.74) | FPR2ANPEP | |
| SCHEMBL14889858 | 0.89 | FPR2 (0.64) | FPR2ANPEP | |
| SCHEMBL19723118 | 0.88 | FPR2 (0.68) | FPR2ANPEPRAB9A | |
| SCHEMBL14889792 | 0.88 | FPR2 (0.68) | FPR2ANPEPRAB9A | |
| SCHEMBL22175170 | 0.86 | FPR2 (0.77) | FPR2ANPEPRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210000846-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-07 | — | — | US | disclosed |
| US-10799518-B2 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | ALLERGAN, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200246360-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2020-08-06 | — | — | US | disclosed |
| US-10434112-B2 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | ALLERGAN, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190153004-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. | 2019-05-23 | — | — | US | disclosed |
| US-10208071-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | ALLERGAN, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-9850264-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | ALLERGAN, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170320897-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170216326-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799518-B2 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | FPR2, FPR1, FPR3 | FPR2 1/4885ANPEP 884/4885RAB9A 4433/4885 |
| US-10208071-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | FPR2, FPR1, FPR3 | FPR2 1/4885ANPEP 1021/4885RAB9A 3573/4885 |
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885ANPEP 884/4885RAB9A 4433/4885 |
| US-20170216326-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885ANPEP 884/4885RAB9A 4433/4885 |
| US-20190153004-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885ANPEP 1021/4885RAB9A 3573/4885 |
| US-20210000846-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885ANPEP 884/4885RAB9A 4433/4885 |
| US-20170320897-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885ANPEP 1021/4885RAB9A 3573/4885 |
| US-20200246360-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885ANPEP 884/4885RAB9A 4433/4885 |
| US-10434112-B2 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | FPR2, FPR1, FPR3 | FPR2 1/4885ANPEP 884/4885RAB9A 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.